Interstitial lung disease safety signal associated with canakinumab: insights from FAERS pharmacovigilance and network toxicology analysis

Canakinumab is a monoclonal antibody targeting interleukin-1β (IL-1β). Although generally well tolerated, scattered reports of interstitial lung disease (ILD) have emerged. This study aimed to explore the potential association between canakinumab and ILD using real-world pharmacovigilance data, and to generate exploratory mechanistic hypotheses through network toxicology analysis. Adverse event reports from the FDA Adverse Event Reporting System (2009 Q2–2026 Q1) were analyzed using the reporting odds ratio and Bayesian information component, with subgroup analyses by indication and sex. Time-to-onset analysis with Weibull shape parameter testing characterized temporal patterns. Network toxicology analysis involved constructing a drug target pool centered on IL-1β, intersecting it with ILD-associated genes, and performing protein–protein interaction network analysis, hub gene identification, and functional enrichment. Among 19,000,026 unique reports, 123 canakinumab-associated ILD cases were identified, yielding a significant signal (ROR 2.10, 95% CI 1.76–2.51). The signal was present in the non-Still’s disease subgroup (ROR 1.43, 95% CI 1.13–1.81) but absent in Still’s disease patients (ROR 0.82, 95% CI 0.60–1.12). The median time to onset was 102.0 days overall with an early-onset Weibull pattern. Thirty-seven overlapping toxicity targets and ten hub genes were identified, forming an IL-1β-centered inflammatory network. Functional enrichment revealed dominant cytokine-mediated signaling, Toll-like receptor, NF-κB, and chemokine pathways, with no enrichment for TGF-β-driven fibrosis. A significant pharmacovigilance signal for ILD was identified in association with canakinumab exposure. Network toxicology analysis generated an exploratory hypothesis involving IL-1β-mediated pulmonary immune dysregulation. These findings warrant further investigation.

Authors

Institutions

Publication Details

Journal
BMC Pulmonary Medicine
Published
2026-11-19
DOI
https://doi.org/10.1186/s12890-026-05009-0
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interstitial lung disease safety signal associated with canakinumab: insights from FAERS pharmacovigilance and network toxicology analysis

Hui Yang, Shuilian Zheng, Fei Wang, Lijiao Chen
BMC Pulmonary Medicine
Pharmacovigilance and Adverse Drug Reactions
article

Interstitial lung disease safety signal associated with canakinumab: insights from FAERS pharmacovigilance and network toxicology analysis

Hui Yang, Shuilian Zheng, Fei Wang, Lijiao Chen
article en

Abstract

Canakinumab is a monoclonal antibody targeting interleukin-1β (IL-1β). Although generally well tolerated, scattered reports of interstitial lung disease (ILD) have emerged. This study aimed to explore the potential association between canakinumab and ILD using real-world pharmacovigilance data, and to generate exploratory mechanistic hypotheses through network toxicology analysis. Adverse event reports from the FDA Adverse Event Reporting System (2009 Q2–2026 Q1) were analyzed using the reporting odds ratio and Bayesian information component, with subgroup analyses by indication and sex. Time-to-onset analysis with Weibull shape parameter testing characterized temporal patterns. Network toxicology analysis involved constructing a drug target pool centered on IL-1β, intersecting it with ILD-associated genes, and performing protein–protein interaction network analysis, hub gene identification, and functional enrichment. Among 19,000,026 unique reports, 123 canakinumab-associated ILD cases were identified, yielding a significant signal (ROR 2.10, 95% CI 1.76–2.51). The signal was present in the non-Still’s disease subgroup (ROR 1.43, 95% CI 1.13–1.81) but absent in Still’s disease patients (ROR 0.82, 95% CI 0.60–1.12). The median time to onset was 102.0 days overall with an early-onset Weibull pattern. Thirty-seven overlapping toxicity targets and ten hub genes were identified, forming an IL-1β-centered inflammatory network. Functional enrichment revealed dominant cytokine-mediated signaling, Toll-like receptor, NF-κB, and chemokine pathways, with no enrichment for TGF-β-driven fibrosis. A significant pharmacovigilance signal for ILD was identified in association with canakinumab exposure. Network toxicology analysis generated an exploratory hypothesis involving IL-1β-mediated pulmonary immune dysregulation. These findings warrant further investigation.

BMC Pulmonary Medicine
Zhejiang Provincial People's Hospital (CN), Hangzhou Medical College (CN)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon